Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Syndax Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 28, 2026 (GLOBE NEWSWIRE) -- SYNDAX PHARMACEUTICALS (NASDAQ: SNDX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING INNOVATIVE CANCER THERAPIES, TODAY ANNOUNCED THAT IT WILL REPORT ITS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON TUESDAY, AUGUST 4, 2026.

SYNDAX TO ANNOUNCE SECOND QUARTER 2026 FINANCIAL RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON AUGUST 4, 2026

EXPANDS PIPELINE WITH SNDX-4321, A NOVEL, MUTANT-SELECTIVE, ALLOSTERIC EGFR INHIBITOR DESIGNED TO ADDRESS NSCLC PATIENT POPULATIONS WITH SIGNIFICANT UNMET NEEDS 

SYNDAX TO HIGHLIGHT LATE-STAGE PROGRAMS AND UNVEIL NEW PIPELINE ASSETS AT R&D EVENT

NEW YORK, JULY 01, 2026 (GLOBE NEWSWIRE) -- SYNDAX PHARMACEUTICALS (NASDAQ: SNDX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING INNOVATIVE CANCER THERAPIES, TODAY ANNOUNCED THAT ON JULY 1, 2026, THE COMPANY GRANTED INDUCEMENT AWARDS TO PURCHASE UP TO 250,700 SHARES OF COMMON STOCK TO EIGHT NEW EMPLOYEES UNDER THE COMPANY'S 2023 INDUCEMENT PLAN. THE STOCK OPTIONS WILL VEST OVER FOUR YEARS, WITH 25% OF THE UNDERLYING SHARES VESTING ON THE ONE-YEAR ANNIVERSARY OF THE VESTING COMMENCEMENT DATE AND 1/48TH OF THE UNDERLYING SHARES VESTING MONTHLY THEREAFTER OVER 36 MONTHS, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE RELATIONSHIP WITH SYNDAX THROUGH THE APPLICABLE VESTING DATES.

SYNDAX PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

REAL-WORLD STUDY OF REVUMENIB SHOWS 82% (9/11) ORR AND 64% (7/11) CR/CRH RATE AMONG R/R NPM1M OR KMT2AR PATIENTS TREATED WITH REVUMENIB MONOTHERAPY OR COMBINATIONS 

SYNDAX SHOWCASES REVUFORJ (REVUMENIB) CLINICAL ACTIVITY IN MULTIPLE ACUTE LEUKEMIA SUBTYPES AND SETTINGS AT EHA 2026

 HIGH RESPONSE RATES OBSERVED WITH THE ALL-ORAL COMBINATION IN A HEAVILY PRETREATED POPULATION, INCLUDING 88% (37/42) ORR, 71% (30/42) CRC, AND 60% CR/CRH (25/42)   STRONG ACTIVITY ACROSS SUBGROUPS, INCLUDING 70% (14/20) CR/CRH IN VENETOCLAX-NAVE AND 50% (11/22) CR/CRH IN VENETOCLAX-EXPOSED PATIENTS   DEEP RESPONSES WITH 80% (24/30) MRD NEGATIVITY AMONG EVALUABLE CRC RESPONDERS   ROBUST TRANSPLANT RATE WITH 45% (19/42) OF PATIENTS PROCEEDING TO TRANSPLANT AND 63% (12/19) RESUMING REVUMENIB POST-TRANSPLANT   ENCOURAGING DURABILITY WITH MEDIAN OVERALL SURVIVAL AFTER TRANSPLANT NOT REACHED   COMBINATION WAS GENERALLY WELL-TOLERATED  NEW YORK, JUNE 11, 2026 (GLOBE NEWSWIRE) -- SYNDAX PHARMACEUTICALS (NASDAQ: SNDX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING INNOVATIVE CANCER THERAPIES, TODAY ANNOUNCED THAT DATA FROM THE PHASE 1/2 SAVE TRIAL OF AN ALL-ORAL REGIMEN OF REVUFORJ (REVUMENIB), DECITABINE/CEDAZURIDINE, AND VENETOCLAX IN RELAPSED OR REFRACTORY (R/R) NPM1 MUTATED (NPM1M), KMT2A-REARRANGED (KMT2AR), OR NUP98-REARRANGED (NUP98R) ACUTE MYELOID LEUKEMIA (AML) WERE PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY AND SIMULTANEOUSLY PRESENTED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2026 CONGRESS IN STOCKHOLM, SWEDEN. REVUFORJ IS THE FIRST AND ONLY MENIN INHIBITOR THAT IS FDA APPROVED FOR PATIENTS ONE YEAR AND OLDER WITH R/R AML WITH A SUSCEPTIBLE NPM1 MUTATION WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS OR R/R ACUTE LEUKEMIA WITH A KMT2A TRANSLOCATION AS DETERMINED BY AN FDA-AUTHORIZED TEST.

SYNDAX ANNOUNCES PUBLICATION OF SAVE DATA ON REVUFORJ (REVUMENIB) IN COMBINATION WITH DECITABINE/CEDAZURIDINE AND VENETOCLAX IN RELAPSED/REFRACTORY NPM1M, KMT2AR, AND NUP98R AML IN THE JOURNAL OF CLINICAL ONCOLOGY

NEW YORK, JUNE 04, 2026 (GLOBE NEWSWIRE) -- SYNDAX PHARMACEUTICALS (NASDAQ: SNDX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING INNOVATIVE CANCER THERAPIES, TODAY ANNOUNCED THAT ON JUNE 1, 2026, THE COMPANY GRANTED INDUCEMENT AWARDS TO PURCHASE UP TO 66,700 SHARES OF COMMON STOCK TO FOUR NEW EMPLOYEES UNDER THE COMPANY'S 2023 INDUCEMENT PLAN. THE STOCK OPTIONS WILL VEST OVER FOUR YEARS, WITH 25% OF THE UNDERLYING SHARES VESTING ON THE ONE-YEAR ANNIVERSARY OF THE VESTING COMMENCEMENT DATE AND 1/48TH OF THE UNDERLYING SHARES VESTING MONTHLY THEREAFTER OVER 36 MONTHS, SUBJECT TO THE EMPLOYEE'S CONTINUED SERVICE RELATIONSHIP WITH SYNDAX THROUGH THE APPLICABLE VESTING DATES.

NEW YORK, JUNE 04, 2026 (GLOBE NEWSWIRE) -- SYNDAX PHARMACEUTICALS, INC. (SYNDAX) (NASDAQ: SNDX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING INNOVATIVE CANCER THERAPIES, HAS ENTERED INTO PRIVATELY NEGOTIATED SUBSCRIPTION AGREEMENTS FOR THE ISSUANCE OF $250.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.25% CONVERTIBLE SENIOR NOTES DUE 2031 (THE NOTES). THE SALE OF THE NOTES IS EXPECTED TO CLOSE ON JUNE 10, 2026, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.

SYNDAX ANNOUNCES PRIVATE PLACEMENT OF $250.0 MILLION OF CONVERTIBLE SENIOR NOTES

 POOLED ANALYSIS OF 24 ADULTS AND CHILDREN WITH KMT2AR, NPM1M, OR NUP98R ACUTE LEUKEMIA WHO RESUMED REVUMENIB POST-TRANSPLANT SHOWS FAVORABLE OUTCOMES, INCLUDING A 2-YEAR OVERALL SURVIVAL RATE OF 90% VS HISTORICAL BENCHMARK OF 51% 

SYNDAX HIGHLIGHTS REVUFORJ (REVUMENIB) DATA PRESENTED AT ASCO 2026, INCLUDING AN ORAL PRESENTATION OF POST-TRANSPLANT DATA

NEW YORK, JUNE 01, 2026 (GLOBE NEWSWIRE) -- SYNDAX PHARMACEUTICALS (NASDAQ: SNDX), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING INNOVATIVE CANCER THERAPIES, TODAY ANNOUNCED THAT IT WILL HOST AN R&D DAY ON TUESDAY, JULY 14, 2026, AT 8:30 AM ET IN NEW YORK CITY. THE R&D DAY WILL FEATURE PRESENTATIONS BY SYNDAX'S MANAGEMENT TEAM AND KEY OPINION LEADERS.

SYNDAX TO HOST R&D DAY HIGHLIGHTING ITS LATE-STAGE PROGRAMS AND EARLY-STAGE ASSETS ON JULY 14, 2026

 ORAL PRESENTATION WILL HIGHLIGHT FAVORABLE OUTCOMES OBSERVED AMONG 21 ADULTS AND CHILDREN WITH KMT2AR, NPM1M, OR NUP98R ACUTE LEUKEMIA WHO RECEIVED REVUMENIB POST-TRANSPLANT 

Syndax Pharmaceuticals, Inc.

SNDX

Price

Financial Reports

No items found.

Press Releases

Syndax Pharmaceuticals, Inc.

SNDX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SNDX